Tyrosinase inhibitory activity of resorcinol derivative and application of resorcinol derivative

By discovering and preparing resorcinol derivatives from Ganoderma lucidum, the problem of insufficient activity of resorcinol derivatives in the prior art was solved, and a significant tyrosinase inhibition effect was achieved, which was suitable for the development of whitening cosmetics.

CN118955249APending Publication Date: 2024-11-15KUNMING INST OF BOTANY CHINESE ACAD OF SCI +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411008235.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The tyrosinase inhibitory activity of the prior art resorcinol derivatives is insufficient, and the 2,4-dihydroxyacetophenone derivatives did not show inhibitory activity in the tyrosinase inhibitory activity experiment, and even promoted melanin production The activity of the skin is not effective in whitening cosmetics.

Method used

A series of resorcinol derivatives were found and prepared from Ganoderma lucidum, including 4-methyl-1,3-renocinol, 4-ethyl-1,3-renocinol, 4-propyl-1, 3-renocinol, 4-butyl resorcinol and 2,4-dihydroxyacetophenone were prepared by structural screening and synthesis to optimize their tyrosinase inhibitory activity.

Benefits of technology

These resorcinol derivatives are significantly better than positive control kojic acid and 377 in the tyrosinase inhibitory activity experiment. They have significant whitening function prospects and can effectively inhibit the production of melanin. They are suitable for the preparation of tyrosinase inhibitors and Whitening cosmetics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955249A_ABST
    Figure CN118955249A_ABST
Patent Text Reader

Abstract

The invention provides resorcinol derivatives, tyrosinase inhibitory activity thereof and application of the resorcinol derivatives in preparation of cosmetics and medicines. Belongs to the technical field of medicines and cosmetics. The dihydroxyacetophenone compound with the whitening effect is found in ganoderma lucidum for the first time, and is one of multiple ganoderma lucidum whitening components with remarkable activity. However, the compound not only is not significant in tyrosinase inhibition activity, but also has a promotion effect. However, on the basis of analysis of the structure of dihydroxyacetophenone, the obtained derivative structure or analogue-resorcinol derivative shows that the obvious tyrosinase inhibitory activity is found, the tyrosinase inhibitory activity of compounds 1-3 and 5-6 exceeds that of positive control kojic acid (Kojic Acid), and the compound can be applied to preparation of drugs and cosmetics for beautifying and whitening.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of medicine and cosmetics, and specifically relates to a class of resorcinol derivatives with tyrosinase inhibitory activity, and applications of the same in the preparation of medicines and beauty and whitening cosmetics. Technical Background

[0002] With the rapid improvement of my country's material living standards, the demand for beauty and whitening cosmetics has increased significantly. Among the cosmetics currently sold on the market, most of them use natural plant functional ingredients as raw materials. Among the whitening functional ingredients of natural origin, kojic acid, niacinamide, arbutin, and vitamin C are all well-known whitening ingredients in my country's cosmetics market. When screening argentin (a whitening ingredient) derived from phenylethylresorcinol (PhenylethylResorcinol, PR) found in the naturally existing European red pine cones, but because argentin is extremely unstable, it needs to be chemically derived and modified. Finally, German whitening experts screened out a new and highly effective whitening active ingredient similar to dihydroargentin - phenylethylresorcinol (and named it 377), its mechanism of action is believed to be: the similarity of its molecular structure to tyrosine can cause tyrosinase to misidentify the molecule and mistake it for tyrosinase, thereby competitively deceiving and inhibiting the activity of the enzyme, reducing the synthesis of melanin. 377)( Figure 1 ) has therefore become a benchmark for tyrosinase inhibition activity and a guide for whitening functional ingredients.

[0003] Lingzhi is one of the most widely used medicinal and edible fungi in cosmetic products. Lingzhi contains many ingredients for cosmetic skin care, the main ingredients are Lingzhi triterpenes, miscellaneous terpenes, steroids, alkaloids, volatile oils, various amino acids, adenine nucleosides, Lingzhi polypeptides, glucose, fructose, pectin, and vitamins B1, B2, niacin, pantothenic acid, etc. Lingzhi's whitening and freckle removal effects: its ability to strongly inhibit the enzyme (tyrosinase) that deposits melanin has also attracted much attention.

[0004] Recently, the inventors found some simple acetophenone compounds in wild Ganoderma lucidum when separating trace components in Ganoderma lucidum. However, in the experiment of inhibiting the formation of melanin in zebrafish embryos, they found that 2,4-dihydroxyacetophenone had very significant activity: in the same experiment, compared with the positive control The inhibition rates of zebrafish embryo melanin formation of 377 (phenylethyl resorcinol) were 82% (c = 0.0025%) and 15% (c = 0.0005%), respectively, and it is a natural product with great whitening function prospects. However, after synthetic preparation and the study of the inhibitory activity of its derivatives on tyrosinase: 2,4-dihydroxyacetophenone (6) and its derivatives not only showed no inhibitory activity in the tyrosinase inhibitory activity experiment, but even showed the activity of promoting melanin production.

[0005] To this end, the present invention collects and prepares a large number of various series of hydroquinone derivatives according to the analysis of active functional groups, and conducts tyrosinase inhibitory activity screening research. From 1,3-hydroquinone derivatives, some functional components with tyrosinase inhibitory activity better than the positive control kojic acid are found. Based on 2,4-dihydroxyacetophenone, a functional component with significant inhibitory activity for zebrafish embryo melanin formation found in Ganoderma lucidum, the present invention collects and prepares hydroquinone derivatives, characterizes their structures and conducts activity screening experiments, and selects several hydroquinone derivatives with strong tyrosinase inhibitory activity as potential whitening functional molecules. Summary of the invention

[0006] The purpose of the present invention is to provide a resorcinol derivative, a pharmaceutical composition containing the same, and the use of the same in the preparation of a tyrosinase inhibitory drug and in the preparation of a cosmetic, in view of the fact that there is no report on the activity of the resorcinol derivative in the prior art.

[0007] In order to achieve the above-mentioned object of the present invention, the present invention provides the following technical solutions:

[0008] The resorcinol derivatives (1-3, 5-6) shown in the following structural formula,

[0009]

[0010] 4-Methyl-1,3-dihydroquinone (1)

[0011]

[0012] 4-Ethyl-1,3-benzenediol (2)

[0013]

[0014] 4-Propyl-1,3-benzenediol (3)

[0015]

[0016] 4-Butylresorcinol (5).

[0017]

[0018] 2,4-Dihydroxyacetophenone (6)

[0019] A cosmetic containing the resorcinol derivative (1-3, 5-6) shown in the structural formula, the cosmetic consisting of an effective amount of any one or any combination of the resorcinol derivative (1-3, 5-6) shown in the structural formula of claim 1, and common cosmetic excipients.

[0020] The application of the resorcinol derivatives (1-3, 5-6) shown in the structural formula in the preparation of tyrosinase inhibitors.

[0021] A pharmaceutical composition containing the resorcinol derivatives (1-3, 5-6) shown in the structural formula, the pharmaceutical composition is composed of an effective amount of any one or any combination of the resorcinol derivatives (1-3, 5-6), and a pharmaceutical excipient or flavoring agent or excipient or gelling agent.

[0022] The application of the pharmaceutical composition in the preparation of tyrosinase inhibitors.

[0023] When the resorcinol derivatives of the present invention are used to prepare medicines or cosmetics, the content of the resorcinol derivatives accounts for 0.1-99% of the mass of the active ingredients, preferably 0.5-90% of the active ingredients, and the rest are pharmaceutical excipients or carriers that are acceptable in pharmacology and pharmaceutical science and non-toxic to humans and animals.

[0024] The preparations are in various dosage forms that can be used clinically, such as capsules, granules, pills, tablets, injections, ointments, tinctures, oral liquids, etc. The dosage forms of the pharmaceutical composition are lyophilized powders, oral liquids, and capsules, etc. The dosage forms of the cosmetics are creams, facial masks, and hydrogels, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 Phenylethyl resorcinol ( 377) Structural diagram;

[0026] Figure 2 It is the process of melanin formation;

[0027] Figure 3 Schematic diagram of the structure of resorcinol derivatives (1-3, 5-6). DETAILED DESCRIPTION

[0028] The substantial content of the present invention is further described below with reference to the accompanying drawings using embodiments of the present invention, but the content of the present invention is not limited thereto.

[0029] Example 1

[0030] Structures of m-dihydroxybenzene derivatives.

[0031] 1) 4-Methyl-1,3-dihydroquinone (1)

[0032]

[0033] Manufacturer: Shanghai Haohong Biopharmaceutical Technology Co., Ltd.; Purity (%): 99.01%

[0034] Molecular formula: C7H8O2; Molecular weight: 124.139

[0035] HR-EIS:125.0597([M+H] + )(Calculated value: 125.147)

[0036] 1 H NMR (600MHz, DMSO-d6) δ: 9.20, 9.09, 6.78, 6.76, 6.20, 6.20, 6.10, 6.10, 6.09, 6.08, 3.80, 2.49.1.94.

[0037] 13 C NMR (150MHz, DMSO-d6) δ: 156.39, 156.24, 131.25, 114.72, 106.39, 102.71, 39.50, 15.64.

[0038] 2) 4-Ethyl-1,3-dihydrobenzene (2)

[0039]

[0040] Manufacturer: Shanghai Haohong Biopharmaceutical Technology Co., Ltd.; Purity (%): 99.71%

[0041] Molecular formula: C8H 10 O2; molecular weight: 138.166

[0042] HR-EIS: 137.0582([MH] + )(Calculated value: 137.158)

[0043] 1 H NMR (600MHz, DMSO-d6) δ: 8.99 (s, 1H), 8.88 (s, 1H), 6.77 (d, J=8.1Hz, 1H), 6.2 3 (s, 1H), 6.10 (d, J = 8.1Hz, 1H), 2.38 (q, J = 7.5Hz, 2H), 1.04 (t, J = 7.4Hz, 3H).

[0044] 13C NMR (150MHz, DMSO-d6) δ: 156.07(C-1), 155.52(C-3), 129.08(C-5), 140.33(C-4), 105.82(C-6), 102.31(C-2), 22.07(CH2), 14.67(CH3).

[0045] 3) 4-propyl-1,3-dihydroquinone (3)

[0046]

[0047] Manufacturer: Shanghai Haohong Biopharmaceutical Technology Co., Ltd.; Purity (%): 98.86%

[0048] Molecular formula: C9H 12 O2; molecular weight: 152.193

[0049] HR-EIS:153.0911([M+H] + )(Calculated value: 153.201)

[0050] 1 H NMR (600MHz, DMSO-d6)6: 8.96 (s, 1H), 8.88 (s, 1H), 6.75 (d, J = 8.1Hz, 1H), 6.23 (d, J = 2.2Hz, 1H), 6.09 (dd, J=8.1, 2.3Hz, 1H), 2.34 (t, J=6.0Hz, 2H), 1.45 (m, J=7.4Hz, 2H), 0.84 (t, J=7.3Hz, 3H).

[0051] 13 C NMR (150MHz, DMSO-d6) δ: 156.09 (C-1), 155.66 (C-3), 129.98 (C-5), 118.69 (C -4), 105.74(C-6), 102.33(C-2), 31.16(α-CH2), 22.88(β-CH2), 13.89(CH3).

[0052] 4) 4-Isopropyl-1,3-dihydroquinone (4)

[0053]

[0054] Manufacturer: Shanghai Haohong Biopharmaceutical Technology Co., Ltd.; Purity (%): 99.87%

[0055] Molecular formula: C9H 12 O2; molecular weight: 152.193

[0056] HR-EIS: 151.0745([MH] + )(Calculated value: 151.185)

[0057] 1 H NMR (600MHz, DMSO-d6) δ: 9.00 (s, 1H), 8.88 (s, 1H), 6.82 (d, J=8.3Hz, 1H), 6.23 (d, J= 2.4Hz, 1H), 6.13 (dd, J=8.3, 2.4Hz, 1H), 3.04 (m, J=6.9Hz, 1H), 1.08 (d, J=6.9Hz, 6H).

[0058] 13 C NMR (150MHz, DMSO-d6) δ: 155.78(C-1), 154.98(C-3), 126.07(C-5), 124.76(C-4), 105.87(C-6), 102.31(C-2), 25.73(CH), 22.85(2xCH3).

[0059] 5) 4-Butylresorcinol (5)

[0060]

[0061] Manufacturer: Shanghai Yuanye Biotechnology Co., Ltd.; Purity (%): 99%

[0062] Molecular formula: C 10 H 14 O2; molecular weight: 166.220

[0063] HR-EIS: 165.0896([MH] + )(Calculated value; 165.212)

[0064] 1 H NMR (600MHz, DMSO-d6) δ: 8.96 (s, 1H), 8.88 (s, 1H), 6.75 (d, J=8.1Hz, 1H), 6.23 (d, J=2.2Hz, 1H), 6.09 (dd, J=8. 1, 2.3Hz, 1H), 2.36 (t, J=12.0, 6.0Hz, 2H), 1.42 (m, J=7.5Hz, 2H), 1.26 (m, J=7.4Hz, 2H), 0.86 (t, J=7.4Hz, 3H).

[0065] 13C NMR (150MHz, DMSO-d6) δ: 156.04 (C-1), 155.62 (C-3), 129.87 (C-5), 118.85 (C-4), 10 5.75(C-6), 102.32(C-2), 32.02(a-CH2), 28.64(β-CH2), 21.98(γ-CH2), 13.91(CH3).

[0066] 6) Synthesis and preparation of 2,4-dihydroxyacetophenone derivatives.

[0067] Overall synthetic preparation method:

[0068]

[0069] In a 10mL round-bottom flask, add 1mmol resorcinol, 1.2mmol acetic acid (or propionic acid, butyric acid, etc.), 3mmol trifluoroacetic anhydride, stir at room temperature for 1 hour (can also be heated, the temperature can be 50℃-150℃), the amount of acid is adjusted appropriately). After the reaction is completed, slowly add 5mL10% NaHCO3 to neutralize the residual acid, then extract with ethyl acetate for multiple times, concentrate the ethyl acetate extract under reduced pressure, wash the extract with distilled water for multiple times to remove residual salt, extract with ethyl acetate for multiple times again and concentrate under reduced pressure, finally use petroleum ether and ethyl acetate for normal phase silica gel column chromatography gradient elution to obtain the pure compound (yield: 30%-80%). The compound structure information is obtained by mass spectrometry and nuclear magnetic resonance methods.

[0070] Structural characterization.

[0071] 1) 2,4-Dihydroxyacetophenone (6)

[0072]

[0073] Yield: 30%-80%; Purity: 98%

[0074] Molecular formula: C8H8O3; Molecular weight: 152.193

[0075] HR-EIS:151.0390([MH] + )(Calculated value: 151.141)

[0076] 1H NMR (600MHz, DMSO-d6) δ (ppm): 12.60 (1H, s, 2-OH), 10.62 (1H, s, 4-OH), 7.74 (1H, brd , J=8.8Hz, 5-H), 6.36 (1H, brd, J=8.8Hz, 6-H), 6.23 (1H, brs, 3-H), 2.50 (3H, s, CH3).

[0077] 13 C NMR (150MHz, DMSO-d6) δ (ppm): 202.70 (C=O), 164.86 (5-C), 164.19 (2-C), 133.71 (C-4), 112.85 (C-1), 108.10 (C-6), 102.28 (C-3), 26.36 (CH3).

[0078] 2) 2,4-Dihydroxypropiophenone (7)

[0079]

[0080] Yield: 30%-80%; Purity: 98%

[0081] Molecular formula: C9H 10 O3; molecular weight: 166.176

[0082] HR-EIS: 165.0366([MH] + )(Calculated value; 165.168)

[0083] 1 H NMR (600MHz, DMSO-d6) δ (ppm): 12.63 (1H, s, 2-OH), 10.58 (1H, s, 4-OH), 7.76 (1H, brd, J = 8.8Hz, 5-H), 6 .35 (1H, brd, J=8.8Hz, 6-H), 6.23 (1H, brs, 3-H), 2.96 (2H, q, J=7.2Hz, CH2), 1.07 (3H, t, J=7.2Hz, CH3).

[0084] 13 C NMR (150MHz, DMSO-d6) δ (ppm): 205.19 (C=O), 164.59 (5-C), 164.13 (2-C), 132 .79(C-4), 112.27(C-1), 108.07(C-6), 102.38(C-3), 30.65(CH2), 8.41(CH3).

[0085] Example 2

[0086] Tyrosinase inhibitory activity assay.

[0087] 1) Experimental principle

[0088] Tyrosinase is a key enzyme in the formation of melanin. By inhibiting the activity of tyrosinase, the production of melanin can be reduced, thereby achieving the purpose of whitening. Tyrosine generates DOPA under the action of tyrosinase, and DOPA is further oxidized by tyrosinase to DOPA quinone, and further oxidized to generate melanin. This experiment uses L-Dopa as a substrate, and the activity of tyrosinase is determined by detecting the production of the product DOPA quinone. Figure 2 .

[0089] 2) Experimental procedures

[0090] The drug to be tested was mixed with tyrosinase (final concentration 25 U / mL), L-Dopa was added to start the reaction, 3 replicate wells were set, and a blank control without drug and a 377 positive control were set at the same time. The OD value was measured by a microplate reader at room temperature for 20 minutes, and the detection wavelength was 490 nm. The tyrosinase activity inhibition rate was calculated.

[0091] The reaction system is shown in Table 1:

[0092] Table 1 Reaction system of tyrosinase activity inhibition rate of resorcinol compounds

[0093]

[0094] 3) Result calculation

[0095] Tyrosinase activity inhibition rate (%) = (1-sample well OD 490nm / OD of experimental control well 490nm )×100%

[0096] 4) Experiment on the inhibitory activity of m-dihydroxybenzene derivatives (1-7) on tyrosinase.

[0097] The tyrosinase inhibitory activity test of m-dihydroxybenzene derivatives (1-7) was carried out, and the results are as follows:

[0098] Table 2 Tyrosinase inhibition rate of resorcinol compounds

[0099]

[0100] The above tyrosinase inhibitory activity test results show that the derivatives with methyl (1), ethyl (2), propyl (3), and butyl (5) substitutions at C-4 in the m-dihydroxybenzene derivatives (1-5) have a tyrosinase inhibitory activity of 50 μM, which exceeds the 72.18% inhibition rate of the positive control kojic acid; only the derivative (4) with isopropyl substitution has a tyrosinase inhibitory activity of 57.82%, which is weaker than the 72.18% inhibition rate of the positive control kojic acid. It is a class of tyrosinase inhibitors with whitening effect development prospects.

[0101] 2,4-Dihydroxyacetophenone (6) was isolated from Ganoderma lucidum and was tested for its inhibitory activity against melanin formation in zebrafish embryos. The inhibition rates of melanin formation in zebrafish embryos of 377 (phenylethyl resorcinol) were 82% (c = 0.0025%) and 15% (c = 0.0005%), respectively, and it is a natural product with great whitening function prospects. However, since the yield of 2,4-dihydroxyacetophenone (6) in Ganoderma lucidum is only 0.000082% (8.2X10 -5 %), 2,4-dihydroxyacetophenone (6) and its analogue 2,4-dihydroxyacetophenone (7) were prepared by organic synthesis; unfortunately, 2,4-dihydroxyacetophenone (6) and its derivatives not only showed no inhibitory activity in the tyrosinase inhibitory activity experiment, but even had the activity of promoting melanin production. This is also an important discovery. In the tyrosinase inhibitory activity experiment, the presence of α-carbonyl does not play a positive role in the tyrosinase inhibitory activity, but has the opposite effect. It also shows that the mechanism of action of meta-diphenol derivatives on the tyrosinase inhibitory activity is quite complicated and worthy of in-depth research. It can not only clarify the stage details of the tyrosinase mechanism of melanin production, but also play a very positive role in the development of efficient and harmless whitening functional molecules.

[0102] Example 3

[0103] Preparation of freeze-dried powder injection of m-dihydroxybenzene derivatives (1-6).

[0104] 1. Materials

[0105] The m-dihydroxybenzene derivative (1-6) was obtained by the same method as in Example 1, and pharmaceutical grade sodium chloride.

[0106] 2. Prescription

[0107]

[0108] 3. Preparation process

[0109] Weigh the prescribed amount of m-dihydroxybenzene derivative (1-6) and sodium chloride, add injection water to the full amount, stir to dissolve completely, and sterilize by intermittent hot pressing. Add 0.3% of medicinal activated carbon and stir for 20 minutes; use a Buchner funnel and a 3.0μm microporous filter membrane to remove the heat source by decarbonization filtration. After the content is qualified, filter with a 0.22μm microporous filter membrane; pack into controlled vials, 0.5mL per bottle, half-stopper, place in a freeze drying box, freeze-dry according to the set freeze-drying curve, stopper, unbox, roll cap, visually inspect and package to obtain the finished product.

[0110] Freeze-drying process: put the sample into the box, lower the partition temperature to -40℃, keep it for 4 hours; lower the cold trap to -50℃, start to evacuate to 250μbar. Start sublimation; raise the temperature to -20℃ uniformly in 1 hour, keep it for 3 hours; raise the temperature to -10℃ uniformly in 3 hours, keep it for 8 hours, and keep the vacuum at 100~250μbar; then dry: raise the temperature to -5℃ in 2 hours, keep it for 2 hours, and keep the vacuum at 150~200vbar; raise the temperature to 10℃ in 0.5 hours, keep it for 2 hours, and keep the vacuum at 80~100μbar; raise the temperature to 40℃ in 0.5 hours, keep it for 4 hours, and evacuate to the lowest vacuum.

[0111] Example 4

[0112] Preparation of capsules of m-dihydroxybenzene derivatives (1-6).

[0113] 1. Materials

[0114] The m-dihydroxybenzene derivative (1-6) obtained by the same method as in Example 1, and food or pharmaceutical grade starch.

[0115] 2. Prescription

[0116]

[0117] 3. Preparation process

[0118] Weigh the prescribed amount of the meta-dihydroxybenzene derivative (1-6) and starch, stir and mix thoroughly, add an appropriate amount of talc, wet granulate with ethanol, sieve and dry, and then fill into No. 2 capsule shells, with each capsule body filled with 60 mg of the meta-dihydroxybenzene derivative (1-7), to prepare meta-dihydroxybenzene derivative (1-6) capsules.

[0119] Example 5

[0120] Preparation of oral solution of m-dihydroxybenzene derivatives (1-6).

[0121] 1. Materials

[0122] The m-dihydroxybenzene derivative (1-6) is obtained in the same manner as in Example 1, and the food or pharmaceutical grade flavoring agent is and caramel flavor.

[0123] 2. Prescription

[0124]

[0125] 3. Preparation process

[0126] Weigh the prescribed amount of m-dihydroxybenzene derivative (1-6), sucrose and caramel essence, add purified water to completely dissolve, filter through a 0.22 μm microporous filter membrane, and fill the filtrate into 2 mL bottles using an oral liquid filling machine. Sterilize after sealing to obtain the product.

[0127] Example 6

[0128] Preparation of m-dihydroxybenzene derivative (1-6) facial cleanser.

[0129] 1. Materials

[0130] The m-dihydroxybenzene derivative (1-6) obtained by the same method as in Example 1 is made of cosmetic grade or food grade raw materials.

[0131] 2. Formulation

[0132] 7g of m-dihydroxybenzene derivative (1-6), 2.0g of glycerin, 4.0g of butylene glycol, 0.5g of propylene glycol, 0.1g of sodium EDTA, 0.3g of guar gum, 2.0g of zinc dioxide, 4.0g of C12-15 alcohol benzoate, 3.0g of C12-20 alkyl glucoside, 0.5g of C14-22 alcohol, 1.2g of cetearyl alcohol, 0.2g of paraben, 0.3g of sodium stearate, 0.5g of polydimethylsiloxane alcohol, 0.2g of polysorbate, and 55g of deionized water.

[0133] 3. Preparation process

[0134] Weigh the prescribed amount of m-dihydroxybenzene derivative (1-6), add purified water to completely dissolve; take glycerol, butylene glycol, propylene glycol, sodium EDTA, guar gum, zinc dioxide, sodium stearate, C12-15 alcohol benzoate, C12-20 alkyl glucoside, C14-22 alcohol, cetearyl alcohol, add purified water to completely dissolve; take paraben, polydimethylsiloxane alcohol, polysorbate, add purified water to completely dissolve. Mix the above-prepared solutions, stir well, filter with a 0.22μm microporous membrane, can the filtrate in 30mL per bottle, seal and sterilize to obtain the product.

[0135] Example 7

[0136] Preparation of facial mask of m-dihydroxybenzene derivatives (1-6).

[0137] 1. Materials

[0138] The m-dihydroxybenzene derivative (1-6) is obtained in the same manner as in Example 1, and other materials are cosmetic grade or food grade raw materials.

[0139] 2. Formulation

[0140] 12g of m-dihydroxybenzene derivative (1-6), 3.5g of xanthan gum, 2.0g of hydrolyzed hyaluronic acid, 2.0g of sodium hyaluronate, 0.3g of propylene glycol, 0.5g of carbomer, 0.1g of paraben, 0.25g of PPG-10 methyl glucose ether, 1.0g of glyceryl glucoside, and 45g of deionized water.

[0141] 3. Mask preparation process

[0142] Step 1: Add deionized water, xanthan gum, hydrolyzed hyaluronic acid, sodium hyaluronate, propylene glycol, carbomer and paraben into an emulsifier and heat to 75°C while stirring. After reaching the temperature, keep warm and continue stirring until the solution is transparent and uniform. Then keep warm for 20 minutes and then cool down to 42°C.

[0143] Step 2: Adjust pH = 7.6 ± 0.2.

[0144] Step 3: Continue to cool to 35°C, add PPG-10 methyl glucose ether, m-dihydroxybenzene derivative (1-6), and glycerol glucoside, continue to stir evenly, and discharge the material after passing the inspection. Coating is performed on a non-woven fabric substrate, with a coating amount of 2.1 g per square centimeter.

[0145] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0146] The above-mentioned embodiments only express several implementation methods of the present invention, and the description is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. A resorcinol derivative (1-3, 5-6) as shown in the following structural formula, 4-Methyl-1,3-dihydroquinone (1) 4-Ethyl-1,3-benzenediol (2) 4-Propyl-1,3-benzenediol (3) 4-Butylresorcinol (5) 2,4-Dihydroxyacetophenone (6).

2. Use of the resorcinol derivatives (1-3, 5-6) represented by the structural formula according to claim 1 in the preparation of cosmetics.

3. A cosmetic containing the resorcinol derivative (1-3, 5-6) represented by the structural formula according to claim 1, characterized in that: The cosmetics are composed of an effective amount of any one or any combination of the resorcinol derivatives (1-3, 5-6) represented by the structural formula described in claim 1, and common cosmetic auxiliary materials.

4. Use of the resorcinol derivatives (1-3, 5-6) represented by the structural formula according to claim 1 in the preparation of tyrosinase inhibitors.

5. A pharmaceutical composition containing the resorcinol derivative (1-3, 5-6) represented by the structural formula according to claim 1, characterized in that: The pharmaceutical composition is composed of an effective amount of resorcinol derivatives (1-3, 5-6, any one or any combination thereof, and a pharmaceutical excipient or flavoring agent or excipient or gelling agent.

6. Use of the pharmaceutical composition according to claim 5 in the preparation of a tyrosinase inhibitor.

Citation Information

Cited By

  • Phenol derivatives 4-ethylphenol and 4-acetonyl phenol, and preparation method and application of phenol derivatives 4-ethylphenol and 4-acetonyl phenol

    CN119504370A